Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Langerhans cell histiocytosis.

K M Herzog1, R R Tubbs

  • 1Cleveland Clinic Foundation, Ohio, USA.

Advances in Anatomic Pathology
|March 30, 1999
PubMed
Summary

Langerhans cell histiocytosis (LCH) is a rare clonal disorder with unknown causes and pathogenesis. Prognosis depends on organ dysfunction and patient age, with treatment for severe cases remaining challenging.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2014
Same author

Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2012
Same author

Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer.

Oncogene·2009
Same author

Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

Stromal gene signatures in large-B-cell lymphomas.

The New England journal of medicine·2008
Same author

Guidelines for HER2 testing in the UK.

Journal of clinical pathology·2004

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Langerhans cell histiocytosis (LCH) is a rare clonal disorder characterized by abnormal Langerhans cell proliferation.
  • The etiology and pathogenesis of LCH remain largely unknown, with no consistent genetic or viral links identified.
  • Altered cytokine and cellular adhesion molecule expression may influence LCH cell migration and homing.

Purpose of the Study:

  • To review the current understanding of Langerhans cell histiocytosis (LCH).
  • To discuss the diagnostic challenges and prognostic indicators for LCH.
  • To highlight the complexities in treating severe and refractory LCH cases.

Main Methods:

  • Review of existing literature on Langerhans cell histiocytosis.
  • Analysis of diagnostic criteria and prognostic factors.
  • Discussion of therapeutic strategies and outcomes for LCH.

Main Results:

  • LCH presents as single or multiple mass lesions with an abnormal Langerhans cell phenotype.
  • Disease behavior varies widely, from spontaneous remission to lethal dissemination, unpredictable by histology.
  • Organ dysfunction and patient age at diagnosis are key prognostic indicators.

Conclusions:

  • The biological potential and classification of LCH remain under investigation, acknowledging its relation to dendritic and macrophage disorders.
  • Effective treatment for severe, refractory LCH remains a significant clinical challenge.
  • Further research is needed to elucidate LCH etiology and improve therapeutic outcomes.

Related Experiment Videos